SPARE-Tau was trained on tau SUVRs to predict clinical status (CU vs MCI/AD) while AD-RAI was trained on T1-weighted MRI volumetric measures also to predict clinical status and quantify brain atrophy. The gene discussed is MAPT; the disease is Alzheimer disease.